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Background: several studies suggest that many asthmatic subjects have uncontrolled asthma.
The control of asthma is now considered the major goal of therapy.
Objectives: to ascertain the level of asthma control, by Asthma Control Test (ACT), in “real-
life” clinical practice and the potential risk factors for uncontrolled disease in patients treated
with inhaled corticosteroids (ICS) and long-acting beta-adrenergic agonists (LABA).
Methods: SERENA is a multi-centre, cross-sectional, 6-month observational, non-interventional
study carried out in 16 Pulmonary Units in Italy. Asthmatic outpatients aged over 18, undergo-
ing treatment with ICS at mediumehigh daily doses associated with LABA, were enrolled. The
patients were divided in 3 subgroups according to the level of asthma control by ACT score
(25:controlled; 20e24:partly controlled; <20: uncontrolled).
Results: Out of a total of 548 patients, 396 met the inclusion criteria. Only 9.1% of patients had
asthma controlled, while partly controlled and uncontrolled asthma accounted for 39.6% and
51.3% respectively. The mean age was 54.5  15.8 and the mean duration of asthma was
16.1  14.1 years. There were more females than males (63% vs 37%) and females had highest
prevalence of uncontrolled asthma (63.1%). The mean values of FEV1% predicted were lower in
the uncontrolled group (p < 0.001). The percentage of patients with at least 1 exacerbation,
unscheduled visit and/or admissions was lower in controlled (22.2%, 8.3%, 8.3%) than in
partly controlled (50%, 38.6%, 9.2%) and uncontrolled (83.2%, 66.2%, 27.8%) groupsIntensive Care Unit, Thoracic Physiopathology Laboratory, AOU Careggi, Florence, Italy. Tel./fax: þ39
areggi.toscana.it, antonio.corrado@aiporicerche.it (A. Corrado).
Study Group are listed in the Appendix section.
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1660 A. Corrado et al.(p < 0.0001). The multivariate ordinal logistic regression analysis identified female sex, FEV1
and exacerbations as the strongest independent factors associated with the uncontrolled
disease.
Conclusion: This study highlights the importance in clinical practice of a periodic assessment
by a validated asthma control instrument and exacerbations/health care contacts during
previous year. Clinicians should be aware that a significant proportion of patients can have
uncontrolled asthma, despite regular pharmacological treatment.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The International Guidelines for the diagnosis and man-
agement of asthma have been available since 1995 [1,2].
Despite the almost annual publication of GINA Guidelines,
the health initiatives undertaken and the asthma control
campaigns, the control of asthma remains a crucial prob-
lem. Several clinical studies suggest that the asthma of
many subjects is still uncontrolled and that asthma
morbidity remains high while the disease seems to be far
from an optimal control [3e6] although effective and safe
treatments, such as inhaled corticosteroids (ICS) and long-
acting beta-adrenergic agonists (LABA) are widely available
[6]. It has been recommended that an effective and safe
treatment must be graded on the basis of a periodic
assessment of asthma control which represents the major
goal of therapy [2,7]. The assessment of asthma control
should include the control of the clinical manifestations
and the control of the expected future risk to the patients
such as exacerbations, losing lung function over time and
side effects of treatment. It has been shown, in a ran-
domized controlled study [8], that combining ICS with LABA
was more effective than ICS alone in achieving the control
of asthma. Recently the Asthma Control Test (ACT) has
been developed and introduced in clinical practice [9e12]
for the assessment of the control of asthma. The test has
shown a good diagnostic accuracy for controlled and not
well controlled asthma but a poor diagnostic accuracy for
the assessment of uncontrolled asthma [13]. At the moment
there are limited data on reliable cut points for identifi-
cation of uncontrolled disease. Up to now all the studies
published, which have tried to identify a relationship be-
tween ACT score and predictors of asthma instability in
adult [14,15], did not include a population with sustained
and homogeneous combined inhaled pharmacological
treatment according to GINA guidelines.
The aim of the present study was to assess, in “real-life”
clinical practice in Italy, the level of asthma control by ACT
and the potential risk factors for uncontrolled disease in
patients undergoing regular treatment with mediumehigh
doses of ICS in association with LABA.Methods
This observational, cross-sectional, non-interventional
multicenter study was promoted by the Italian Association
of Hospital Pulmonologists (AIPO: Associazione Italiana
Pneumologi Ospedalieri) and was carried out from the 4th
February 2010 to 11th April 2011 in outpatient clinics of 16Italian Pulmonary Units. The protocol was approved by the
local ethics committees of all the participating centres. All
patients provided their written informed consent to
participate in the study. All asthmatic patients 18 years-
old of both genders, according to GINA guidelines [1,2], and
on regular treatment with LABA plus ICS at medium/high
daily doses (beclomethasone dipropionate e HFA
>250e500/>500e1000 mcg or estimated equipotent daily
doses of other ICS for adults) attending the outpatient
clinic of each centre were considered eligible for the study
and registered in the electronic database developed by
AIPO. In each unit, one or more specialists filled out an
electronic Case Report Form (e-CRF) with clinical infor-
mation on patients with a confirmed diagnosis of Asthma.
The e-CRF required the following basic information: de-
mographic data, history of smoking, year in which asthma
was first diagnosed, type of asthma according to the
allergometric tests, spirometric data Forced Expiratory
Volume in one second (FEV1) and FEV1/Forced Vital Ca-
pacity (FEV1/FVC) measured in the last three months,
symptoms reported by the patient at the time of the visit
and referred to the last 4 weeks, current pharmacotherapy,
number of exacerbations, number of visits to the emer-
gency room or unscheduled visits in the preceding year.
Presence and type of co-morbidities (cardiovascular, dia-
betes, obesity, dyslipidemia, gastro-oesophageal reflux,
rhinitis, nasal polyposis, obstructive sleep apnoea e OSA,
chronic renal failure, osteoporosis and depression) were
also registered. The level of asthma control of each patient
was assessed by means of the Asthma Control Test (ACT)
questionnaire [9]. The total score ranges from 5 to 25
points. On the basis of the points scored, we divided the
patients in three subgroups (controlled, ACT Z 25; partly
controlled, ACTZ 24e20; and uncontrolled, ACT<20). The
choice of these cut-off values was made a priori before the
analysis of data on clinical consideration taking into ac-
count that 25 points scored represents a patient with
asthma totally free of symptoms and a complete control of
the disease. All the e-CRFs were sent on-line to the central
database of the AIPO Study Centre for data processing
and analysis that was blind with regard to the patient’s
identity.
All centres were asked to recruit consecutively within 6
months the patients who had attended their units and
complied with the following inclusion criteria:
 aged >18;
 clinical diagnosis of asthma according to the GINA
guideline version existing at the time of the study [1]
and in treatment with long-acting bronchodilators
Assessment of asthma control 1661(LABA) plus Inhaled corticosteroids (ICS) at medium/
high daily doses [1,2].
The Exclusion Criteria were as follows:
 clinical features suggesting emphysema or chronic
bronchitis;
 refusal to participate;
 other de-compensated organ failures;
 known neoplastic diseases;
 severe psychiatric disorders;
 participation in an asthma-related research study
within the previous 3 months.
All medical treatments were within normal clinical
practice, the decision to prescribe any treatment was
completely independent from the decision to include the
patient in the study.
Data analysis
Results were given as means (SD) for normally distributed
data, as medians with the Interquartile range (IQR) for non-
normally distributed variables, and as percentages for
categorical variables. The Student test was used for the
comparison between means having first checked the
assumption of equality of variances by the F test. The
analysis of variance (ANOVA) for repeated measurements
was used to test the difference between the means of
several subgroups of a variable (multiple testing) having
first checked the assumption of equality of variances by
relying on the Bartlett test or the Bonferroni test for mul-
tiple comparisons when needed. When the assumption of
equality of variances was violated, the KruskalleWallis test
was used. Bivariate analyses were conducted with the chi-
square test or the exact Fisher test (for categorical vari-
ables) and the two tailed t-tests. A multinomial regression
model was fitted to the data by using asthma control
(controlled, partly controlled, and uncontrolled) as
dependent variable to identify the factors associated with
asthma control. Multivariate associations of potential de-
terminants with asthma control were expressed by relative
risk ratios (using controlled asthma as the reference cate-
gory) and their 95% CI. All the variables considered for the
univariate analysis were included in the multinomial
regression model. For all tests a p value of 0.05 was
considered statistically significant. Analyses were per-
formed by R 2.15.2 and Med-Calc (version 11.0.0.0).
Results
Of the 16 Units involved in the study, 5 withdrew after
initial acceptance for technical reasons such as limited in-
ternal organization or lack of time. The final data were
collected in 11 units. From the 4th February 2010 to 11th
April 2011, 548 patients were enrolled but only 396 were
included in the analysis because the ACT score was lacking
in 26 patients while in 126 patients the inclusion criteria
were violated regarding the doses of ICS. The median
number of cases contributed by units was 22, range
(1e175), and the interquartile range (IQR) was 8 and 33.Characteristics of the patient population
Table 1 shows the characteristics of patients divided into
the three subgroups according to the ACT score. Among the
396 patients: 36 (9.1%) had controlled asthma whereas 157
(39.6%) and 203 (51.3%) had partly controlled and uncon-
trolled asthma, respectively. The distribution of patients in
the three subgroups was statistically different (P < 0.0001)
with the highest percentage in the uncontrolled group. As
reported in Table 1, patients with uncontrolled asthma
were older than the other two groups. A higher proportion
of females than males was found in the uncontrolled
asthma group. By contrast, there was a greater prevalence
of males in the partly and controlled asthma groups,
respectively. Only 31 of 396 patients were current smokers,
and the majority of them presented an uncontrolled
asthma. The Body Mass Index was not different in the three
subgroups of patients. The duration of asthma from the first
diagnosis was longer and statistically significant in patients
with uncontrolled asthma. Spirometry was available in 380/
396 patients (95.9%). The mean values of FEV1% predicted
differed significantly across the groups of patients with
different ACT scores, with the lower value in the uncon-
trolled asthma group (P < 0.001).
Co-morbidities
As reported in Table 1, 62.1% of patients were suffering
from at least one co-morbidity. The rate of co-morbidities
differed significantly across the three subgroups from 9.8%
in controlled to 39.0% and 51.2% in partly and uncontrolled
asthma respectively (p < 0.0001). Cardiovascular disorders
(30,1%) and rhinitis/nasal polyposis (28.0%) were the most
representative co-morbidities. Systemic hypertension alone
represented the 23.5% of all co-morbidities. Obesity was
present in 17.2% of patients, metabolic disorders (diabetes
and dyslipidemia) in 15.6%, gastro-oesophageal reflux in
13.1%, obstructive sleep apnoea (OSA) in 2.78%, osteopo-
rosis in 2.53%, chronic renal failure (CRF) in 0.25% and
depression in 1.8% of all patients. The distribution of the
co-morbidities according to the control of asthma by ACT is
reported in Table 2. With the exception of OSA, CRF and
depression the percentage of each co-morbidity was higher
and statistically significant in uncontrolled asthma. Out of
the 246 patients with co-morbidities, 104 presented one co-
morbidity and 140 had two or more co-morbidities. The rate
of distribution according to the ACT is reported in Table 2.
Pharmacological treatment
All patients recruited were treated with LABA plus medium/
high daily doses of ICS. Table 3 illustrates the type of drugs
used by the 396 patients and according to the ACT scores.
ICS/LABA was used alone in 344 patients (86.9%), in associ-
ation with systemic corticosteroids per os in 34 (8.6%), and
regularly associated with short acting beta agonists (SABA) in
18 (4.5%). SABA as needed were used in 36.7% of patients
exclusively with partly and uncontrolled asthma.
As reported in Table 3, the use of systemic corticoste-
roids per os associated to ICS/LABA was detected mainly in
patients with uncontrolled asthma, whereas SABA as
Table 1 Characteristics of the patients according to the control of asthma by ACT.
Characteristics All patients
(N Z 396)
ACT Z 25
(N Z 36)
9.1%
ACT Z 24e20
(N Z 157)
39.6%
ACT <20
(N Z 203)
51.3%
p Value
<0.0001
Age, years, Mean (SD) 54.5 (15.8) 52.7 (13.6) 52.3 (15.7) 56.5 (16.0) 0.036*
Male sex, % (n pts) 37.1 (147) 12.2 (18) 56.5 (83) 31.3 (46) <0.0001
Female sex, % (n pts) 62.9 (249) 7.2 (18) 29.7 (74) 63.1 (157)
Smoking
Yes, % (n pts) 26.5 (105) 6.7 (7) 48.6 (51) 44.8 (47) 0.092
No, % (n pts) 73.5 (291) 10 (29) 36.4 (106) 53.6 (156)
Current smoker, % (n pts) 7.8 (31) 3.2 (1) 35.5 (11) 61.3 (19) 0.050#
Ex smoker, % (n pts) 18.7 (74) 8.1 (6) 54.0 (40) 37.8 (28)
No smoker, % (n pts) 73.5 (291) 9.97 (29) 36.4 (106) 53.6 (156)
BMI (kg/m2), Mean (SD) 27 (4,9) 28.1 (5.4) 26.7 (4.9) 26.7 (4.8) 0.318**
Years from the first diagnosis, Mean (SD) 16.1 (14.1) 14.6 (13.3) 13.85 (14.7) 18.05 (14.45) 0.015***
FEV1% pred, Mean (SD) in 380 patients 80.7 (16.8) 92.1 (11.6) 84.4 (15.3) 75.7 (17.0) 0.0001x
FEV1/FVC in 380 patients 70.9 (13.9) 70.6 (13.4) 71.5 (12.8) 70.4 (14.7) 0.7400xx
Presence of at least 1 co-morbidity, % (n pts)
Yes 62.1 (246) 9.8 (24) 39.0 (96) 51.2 (126) <0.840###
No 37.9 (150) 8.0 (12) 40.7 (61) 51.3 (77)
 Pearson Chi-square 112,742; *ANOVA, One-way analysis of variance, F-ratio 3359;  Pearson Chi-square 37,420, Chi-square trend
29,366;  Fisher’s exact test; # Pearson Chi-square 15,742; # Fisher’s exact test; **ANOVA, One-way analysis of variance, F-ratio 1.149;
***ANOVA, One-way analysis of variance, F-ratio 4.271; xKruskalleWallis equality of populations rank test Chi-square 41,442 on 380 pts
(patients: 34 ACT Z 25; 153 ACT 20e24; 193 ACT<20); xx ANOVA, One-way analysis of variance, F-ratio 0,30; ### Fisher’s exact test.
1662 A. Corrado et al.needed were used exclusively in partly and uncontrolled
asthma. The type and the daily dosages of drugs used were
reported in Supporting information.
Exacerbations, admission to ED and unscheduled
visits
Exacerbations
As shown in Table 3 the majority of patients, 253 (64.5%),
reported at least one exacerbation during the previous yearTable 2 Co-morbidities according to ACT.
Co-morbidities Number of patien
with co-morbiditie
Panel A. Distribution of co-morbidities according to the ACT
Cardiovascular disorders % (n pts) 108@
Rhinitis/nasal polyposis % (n pts) 111
Obesity % (n pts) 68
Metabolic disorders % (n pts) 55#
Gastro-esophageal reflux % (n pts) 52
Obstructive Sleep Apnoea e OSA % (n pts) 11
Osteoporosis % (n pts) 10
Depression % (n pts) 7
Chronic renal failure % (n pts) 1
Panel B. Distribution of patients with one or 2 co-morbidities
1 Co-morbidity % (n pts) 106
2 Co-morbidities % (n pts) 140
Panel A: @11 patients had 2 co-morbidities associated for a total o
1.1018519); #7 patients had 2 co-morbidities associated for a tot
1.1272727); *Chi-square Z 39.389; chi-square Z 24.703; C^hi-square
square Z 4.545; Chi-square Z 6.200; C^hi-square Z 0.571; xxChi-sq
Panel B: *Chi-square Z 21.189; Chi-square Z 49.900.of the study. The rate of distribution of exacerbations
through the subgroups of patients increased in a statisti-
cally significant way from 22.2% in controlled to 50.0% and
83.2% in partly and uncontrolled asthma respectively. This
trend was statistically significant (P < 0.0001).
Admission to the emergency department
The majority of patients 315 (81.4%) did not experience an
admission to the emergency department (ED) because of
the exacerbation of asthma. Among the 72 (18.6%) patientsts
s
ACT Z 25 ACT Z 24e20 ACT <20 p Value
10.1 (11) 30.5 (33) 59.2 (64) <0.0001*
11.7 (13) 48.6 (54) 39.6 (44) <0.0001
10.3 (7) 36.7 (25) 52.9 (36) 0.001^
7.3 (4) 27.3 (15) 65.5 (36) <0.0001x
1.9 (1) 36.5 (19) 61.5 (32) <0.0001&
18.2 (2) 63.6 (7) 18.2 (2) 0.1030**
10 (1) 20 (2) 70 (7) 0.045
0 (0) 28.6 (2) 71.4 (5) 0.4497^ ^
0 100 (1) 0 NDxx
according to the ACT
12.3 (13) 43.4 (46) 44.4 (47) <0.0001*
7.9 (11) 35.7 (50) 56.4 (79) <0.0001
f 119 co-morbidities (cardiovascular co-morbidities per patient:
al of 62 co-morbidities (metabolic co-morbidities per patient:
Z 18.912; x chi-square Z 28.836; & chi-square Z 27.962; **Chi-
uare Z Not Detectable.
Table 3 Pharmacological treatment, exacerbations, admission to ED and unscheduled visits of the patients according to the
control of asthma by ACT.
Treatment All patients
(N Z 396)
ACT Z 25
(N Z 36)
ACT Z 24e20
(N Z 157)
ACT < 20
(N Z 203)
p Value
ICS/LABA, % (n pts) 86.9 (344) 10.2 (35) 40.70 (140) 49.13 (169) 0.0138a
ICS/LABA + CS per os, % (n pts) 8.6 (34) 2.94 (1) 20.60 (7) 76.50 (26)
ICS/LABA + SABA, % (n pts) 4.5 (18) 0.0 (0) 55.55 (10) 44.44 (8)
Exacerbation All patients
(N Z 392)
ACT Z 25
(N Z 36)
ACT Z 24e20
(N Z 154)
ACT < 20
(N Z 202)
p Value
0, % (n pts) 35.5 (139) 77.8 (28) 50.0 (77) 16.83 (34) <0.0001b
>1, % (n pts) 64.5 (253) 22.2 (8) 50.0 (77) 83.17 (168)
Admission to ED All patients
(N Z 387)
ACT Z 25
(N Z 36)
ACT Z 24e20
(N Z 153)
ACT < 20
(N Z 198)
p Value
0, % (n pts) 81.4 (315) 91.67 (33) 90.85 (139) 72.22 (143) 0.0001c
>1, % (n pts) 18.6 (72) 8.33 (3) 9.15 (14) 27.78 (55)
Unscheduled visits All patients
(N Z 387)
ACT Z 25
(N Z 36)
ACT Z 20e24
(N Z 153)
ACT < 20
(N Z 198)
p Value
0, % (n pts) 50.1 (194) 91.67 (33) 61.4 (94) 33.8 (67) <0.0001d
>1, % (n pts) 49.9 (193) 8.33 (3) 38.6 (59) 66.2 (131)
a Pearson Chi-square: 12.538.
b Pearson Chi-square: 73.05; Chi-square trend 72.809.
c Fisher’s exact test.
d Pearson Chi square: 72.0919.
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in those with an uncontrolled asthma, Table 3.
Unscheduled visits
This information was missing in 9 patients. Fifty percent
(193/387) of patients reported one or more unscheduled
visits during the previous year and the need for unsched-
uled visits increased significantly when the control of
symptoms according to ACT Score was poorest. Table 3.
A univariate ordinal logistic regression analysis of all
patients using the ACT classification as dependent variable
and gender, age, weight, height, years of asthma from
the first diagnosis, smoking habit, FEV1, pharmacological
treatment, exacerbation of asthma, admission to the ED,
and unscheduled visits as independent variables is
reported in Table S1. Table 4 reports the multivariateTable 4 Multivariate ordinal logistic regression in 371 patients
Variables Odds ratio Std.
Gender (Female vs Male) 0.3147952 0.093
Unscheduled visits 1.607771 0.532
Height 0.978418 0.014
Exacerbations 3.287085 1.132
Pharmacological treatment
LABA/ICS þ CS per os 1.867688 0.868
FEV1 0.9636538 0.007
Variables included in the model: gender, age (as continuous variable),
the first diagnosis, FEV1, admission to ED, unscheduled visits, exacerb
variables included in the table were retained in model with stepwise
removal from the model of 0.2.ordinal logistic regression in 371 patients with asthma
using the ACT classification as dependent variable and as
independent variables all those included in the univariate
analysis. Only the variables reported in the table were
retained in model using a stepwise method and with a
significance level for removal from the model of 0.2. Fe-
male sex, exacerbation and FEV1 were the most predictive
of lack of asthma control. The estimated odds in female vs
males was 3.2. This means that females have a 3.2 times
higher risk than males of having uncontrolled or less
controlled asthma. Exacerbations contributed signifi-
cantly to the lack of control of asthma with odds of 3.28.
Patients with higher values of FEV1 showed a better con-
trol of asthma, the odds of patients with a point FEV1
higher was 0.96 times than those who didn’t show a point
increase in FEV1.with asthma using ACT classification as dependent variable.
error p 95% Confidence interval
4723 0.0001 0.1759059e0.5633468
789 0.152 0.8397495e3.078211
6306 0.145 0.9501587e1.007518
074 0.0001 1.673619e6.456026
0571 0.179 0.7510797e4.644325
6904 0.0001 0.9486981e0.9788453
weight (Kg), height (cm), pharmacological treatment, year from
ations, presence of at least one co-morbidity, smoking habit. The
multivariate ordinal logistic regression, with significance level for
1664 A. Corrado et al.Fig. 1 shows the distribution of asthmatic patients
treated with medium or high doses of ICS alone and me-
dium/high doses of ICS with oral steroids (OS) according to
the level of asthma control. The patients treated with high
doses of ICS without OS presented a risk 1.72 times higher
than those treated with medium doses of ICS without OS for
partly or uncontrolled asthma; OR 1.72, (95% CI
1.1716e2.5216), p Z 0.0056. The patients treated with
medium/high doses of ICS with OS presented a risk 2.80
times higher than those treated with medium/high doses of
ICS without OS for partly or uncontrolled asthma; OR 2.80
(95%CI 1.3671e5.7529), p Z 0.0049.Discussion
The data of our study show that the control of asthma is far
from being achieved in real life. Our data extend and
support previous observation showing that only a minority
of asthmatic patients attains the control of asthma
[4,5,16]. In our study, only 9.1% of patients had their
asthma under control while a partly controlled and un-
controlled asthma accounted for 39.6% and 51.3% of pa-
tients respectively. Our analysis included only patients (396
out of 548) with a longstanding diagnosis of asthma and who
were treated with medium/high doses of ICS associated to
LABA. Our data shows that female sex, an age older than
fifty, the years of asthma from the first diagnosis, treat-
ment with ICS/LABA þ CS per os, FEV1, unscheduled visits,
exacerbations, admission to the emergency department
were each individually associated with an increased risk of
uncontrolled disease. The multivariate analysis which en-
compasses all these factors showed that gender, exacer-
bations and FEV1 were the strongest independent factors
associated with uncontrolled asthma.
Several controlled studies in the last decade have shown
that the control of asthma can be obtained in a large pro-
portion of patients using inhaled steroids alone or in com-
bination with long-acting b2-agonists [8,17,18]. Controlled
Clinical Trials, however, do not always reflect real-life
conditions, and epidemiological studies in the generalFigure 1 Percentage of distribution of asthmatic patients
treated with medium or high doses of Inhaled Corticosteroids
alone plus LABA or medium/high doses of ICS plus LABA and
oral steroids according to ACT classification.population clearly show that asthma is far from being
adequately controlled [3e5,11,19]. The rate of uncon-
trolled asthma reported in several studies
[5,10,11,15,20e23] ranges from 49 to 69%. These results
are consistent with the percentage of 51.3% reported in our
study. However it must be pointed out that all previous
studies, in which ACT was used for the assessment of
asthma control in adults, included a heterogeneous popu-
lation with regard to the therapeutic regimen. ICS/LABA
were used in different percentages from 49.9% [14] to 55%
[4] or it was not reported [15,24]. In our survey we found,
despite a maximal treatment with high doses of inhaled
corticosteroids associated to LABA, a high rate of uncon-
trolled asthma. When oral corticosteroids were added to
the inhaled association the rate of uncontrol was higher.
This finding is in keeping with that reported in other studies
[25,26]. Sullivan et al. [25], using the asthma therapy
assessment questionnaire (ATEQ) to evaluate the risk of
subsequent asthma-related health care events in adult
asthma patients, found that patients with three or four
control problems were at significantly greater risk for oral
steroids burst (RR 2.9) vs patients with no control problem.
Gold et al. [26] reported that uncontrolled asthma was
associated to use of oral steroids (OR, 2.5) compared with
patients with controlled asthma. In a recent post hoc
analysis of five large clinical trials [27] the need of oral
steroids treatment was included in the definition of severe
asthma exacerbations.
Smoking is reported [2,28] as a factor associated to a
limited control of asthma. In our survey we found that a
history of post-tobacco smoking was associated with
reduced asthma control (pZ 0.040, OR 0.4208). It has been
reported [29] an increased risk of asthma higher in ex-
smokers (OR 1.49) than in current smokers (OR 1.33)
compared to non-smokers. The lighter effect in current
smokers was hypothesized as due to a behavioural change
as a response to beginning symptoms. Recently the impact
of smoking on asthma has been evaluated in a large
population-based international study [30]; the authors re-
ported the highest mean of symptom score in ex-smokers.
Asthma is often associated with various co-morbidities,
which may influence the asthma control and the response
to treatment [31]. We found that the rate of the most
representative co-morbidities such as Cardiovascular dis-
orders, Rhinitis/nasal polyposis, obesity, metabolic disor-
ders, gastro-oesophageal reflux and osteoporosis was higher
in patients with uncontrolled asthma. Furthermore when
we look at the association of more co-morbidities in a single
patient we found that patients with 2 co-morbidities
presented the highest rate of uncontrolled asthma. How-
ever, the weight of the presence of co-morbidities in the
multivariate analysis was weak. Peters et al. [4], on the
contrary, reported that chronic sinusitis, high blood pres-
sure and gastro-oesophageal reflux were strongly related to
uncontrolled asthma in a multivariate analysis. This
discrepancy may be due in our opinion to the different
sample of patients (396 vs 1811). Identification and treat-
ment of co-morbidities is now recognized as an integral part
of core management of asthma particularly in the more
severe forms of the disease, even-though the effect of
treating co-morbidities on asthma severity and long-term
clinical outcomes needs to be further investigated [31].
Assessment of asthma control 1665Achieving adequate asthma control and minimizing
future risk of exacerbations are the primary goals in the
management of the disease. The prediction of exacerbation
by means of clinical tool is a crucial aspect for the correct
management of asthma.
It has been reported that validated asthma control
questionnaire ACQ-5 [32], full composite ACQ7 [33] and
ATAQ [25] are associated with future risk of asthma exac-
erbations and the risk of subsequent severe asthma-related
health care events. Bateman et al. [32] in a retrospective
pooled analysis of 5 studies classified the patients in two
groups by their baseline ACQ-5 score. The patients with a
baseline ACQ-5 score 1.5 vs those with a score <0.5 had a
significantly higher exacerbation rate over 12 month
period. Meltzer et al. [33] reported that each 1 point in-
crease in ACQ was associated with a 50% increased risk of
exacerbation for the following two week period.
Ko et al. [14] reported that in adult asthmatic patients
a single measurement of ACT was useful for prediction of
exacerbation and changes in treatment decision. Stan-
ford et al. [15], employing ACT and C-ACT, found a pos-
itive relationship between uncontrolled asthma and
exacerbations only in children. In our study we found
that exacerbation was a strong predictor of uncontrolled
asthma in adult asthmatic patients treated with moder-
ate to high doses of ICS/LABA. Why our asthmatic pa-
tients, treated following international guidelines, have
such a high percentage of either partly or uncontrolled
disease? The explanation may lay on the hypothesis
formulated by Bateman et al. [32] in their retrospective
pooled analysis of 5 studies in which they reported that
the achievement of current control in around 40% of the
patients included in the analysis reflects the relatively
refractory nature of their asthma and the limitations of
the treatment used.
We acknowledge that our study has several limitations.
The first is that in filling out the e-CRF, the pulmonary
specialist might have been a different doctor from the
caring physician. Furthermore, we did not record whether
the pharmacological prescription originated from a pul-
monologist, another specialist (geriatrist, internist, etc.) or
a general practitioner. The second, as previously
mentioned, was the fact that we did not ascertain whether
the patients were actually taking the prescribed medica-
tions, there is no effective and accurate manner in which to
measure true asthma medication adherence and we do not
know if patients received a written management plan.
Finally, the population of this study was not the result of an
epidemiological design, but only represented patients who
referred to the clinic of the units participating in the study.
Pulmonary function testing and a current asthma
symptom alone might not accurately reflect the level of
asthma severity and control [4,34,35]. Our findings sup-
port the need for a more global regular assessment of
asthma severity and control, including asthma-related
health care use and medication use. Moreover, a formal
asthma control assessment (such as ACT) should be con-
ducted at each clinical visit to improve the likelihood of
achieving asthma control. Finally clinicians should be
aware that a significant proportion of patients have an
uncontrolled disease despite treatment in accordance
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